Business
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU Norwood, MA, May 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2020 E-Congress that will be taking place June 3-6, 2020.\n Summarized below are the abstract titles that were selected for publication. The abstracts are published in the electronic \"Abstract Book,” which is an official supplement to the \"Annals of Rheumatic Diseases ARD.” The publications are also available in the Scientific Publications section of Corbus’ website. Programme Number AB0152: Title: Lenabasum, a CB2 agonist, inhibits inflammasome activationAuthors: Subba Chintalacharuvu, Corbus Pharmaceuticals, Inc.; Ping Zang, Corbus Pharmaceuticals, Inc.; Barbara White, M.D., Corbus Pharmaceuticals, Inc.; Sergei Atamas, M.D., Ph.D., Corbus Pharmaceuticals, Inc.Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1372 Programme Number AB0568: Title: Baseline European Patient Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum, a CB2 Agonist, in Diffuse Cutaneous Systemic SclerosisAuthors: Robert Spiera, M.D., Hospital for Special Surgery Main Hospital, New York; Nancy Dgetluck, Corbus Pharmaceuticals, Inc.; Bradley Bloom, M.D., Corbus Pharmaceuticals, Inc.; Barbara White, M.D., Corbus Pharmaceuticals, Inc.; Christopher Denton, M.D., Ph.D., FRCP, University College LondonCitation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1576 About Lenabasum Lenabasum is a rationally designed, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2), resolves inflammation and limits fibrosis. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. In both animal and human studies conducted to date, lenabasum has induced the production of pro-resolving lipid mediators that activate endogenous pathways which resolve inflammation and speed bact...